Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ahmad Tarhini, MD, PHD
Moffitt Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Angeles Clinic and Research Institute
Los Angeles, California, United States
Inderjit Mehmi, MDRecruiting - Moffitt Cancer Center
Tampa, Florida, United States
Ahmad Tarhini, MD, PHDRecruiting - University of Chicago Medical Center
Chicago, Illinois, United States
Daniel Olson, MDRecruiting - Northwell Health Center for Advanced Medicine
New Hyde Park, New York, United States
Shaheer Khan, DORecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Nov 2024
- Primary completion
- 31 Oct 2030
- Completion
- 31 Oct 2030
- Last update posted
- 4 Dec 2025
- Registered enrollment
- 32
- Registry id
- NCT06121180
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.